GlassScriptPhysician profile
Yini Kong
NPI 1538637038
$954.02
in general payments reported to CMS, 2019-2025
15 companies · $488 in 2025
The $488 reported for 2025 was more than what 92% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $95.18 · 2024: $226 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $253.93 | 2024-2025 | Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $215.74 | 2022-2025 | Nucala |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2021 | |
| Genzyme Corporation | $70.52 | 2024-2025 | |
| Neurelis, INC. | $62.15 | 2024-2025 | Valtoco |
| Hologic Sales and Service, LLC | $34.22 | 2022 | |
| Tolmar, INC. | $33.14 | 2024-2025 | Fensolvi |
| Biomarin Pharmaceutical INC. | $32.38 | 2025 | Brineura |
| Abbvie INC. | $22.25 | 2022 | |
| Ucb, INC. | $21.05 | 2025 | Nayzilam |
| Agile Therapeutics, INC. | $19.60 | 2021 | |
| Digestive Care, INC. | $17.51 | 2024 | Pertzye |
| Seqirus USA INC | $16.70 | 2022 | |
| Rare Disease Therapeutics, INC. | $15.51 | 2025 | Purixan |
| Sanofi-Aventis U.S. LLC | $14.32 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yini Kong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.